title: Clinical characteristics of patients with relapsed multiple myeloma.
abstract: Although survival outcomes have improved over the last decade for patients with multiple myeloma (MM), few patients remain free of disease and most inevitably relapse. Selecting a treatment for patients with relapsed MM is challenging given the number and diversity of regimens patients may have previously received, which can affect subsequent therapeutic choices. Importantly, a number of patient- and disease-related factors can also have an effect on treatment choice, treatment efficacy, and tolerability; thus, an understanding of the heterogeneity of patients in the setting of relapsed MM is important for appropriate treatment selection. Here, we review select patient and disease characteristics reported in key interventional and observational studies in relapsed MM (including age, sex, race, and the presence of high-risk disease, renal impairment, or peripheral neuropathy at baseline) to examine common and disparate features of patients with relapsed MM. As therapeutic regimens can have varying efficacy and/or tolerability in patients depending on these factors, we also provide treatment recommendations for patients with select baseline characteristics.
authors: National and Kapodistrian University of Athens, School of Medicine, 80 Vas. Sofias Avenue, Athens 11528, Greece. Electronic address: mdimop@med.uoa.gr.
authors: Meletios A
authors: MA
authors: Dimopoulos
authors: National and Kapodistrian University of Athens, School of Medicine, 80 Vas. Sofias Avenue, Athens 11528, Greece. Electronic address: eterpos@hotmail.com.
authors: Evangelos
authors: E
authors: Terpos
authors: Weill Cornell Medical College/New York Presbyterian Hospital, Myeloma Center, 428 East 72nd Street, Oxford 300, New York, NY 10021, United States. Electronic address: run9001@med.cornell.edu.
authors: Ruben
authors: R
authors: Niesvizky
authors: Department of Hematology, University of Torino, Via Genova 3, 10126 Torino, Italy. Electronic address: appalumbo@yahoo.com.
authors: Antonio
authors: A
authors: Palumbo
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local; D020364:Paraneoplastic Polyneuropathy / Q000209:etiology; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D012737:Sex Factors
chemical_list: D007155:Immunologic Factors; D061988:Proteasome Inhibitors
keywords: Immunomodulatory drug; Multiple myeloma; Proteasome inhibitor